October 22, 2023
4 min watch
Save
VIDEO: Researchers investigate tyrosine kinase inhibitors for wet AMD
Issue: November 25, 2023
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio Video Perspective, Sophie J. Bakri, MD, discusses data presented at the Retina Society meeting that investigated the antiangiogenic profiles of three tyrosine kinase inhibitors: vorolanib, axitinib and sunitinib.
“While all the TKIs that we studied can inhibit all VEGF receptors and were shown to inhibit angiogenesis better than bevacizumab, vorolanib accomplished these things without impacting Tie-2 function and without binding melanin,” she said.
Published by:
Sources/Disclosures
Collapse
Source:
Bakri S. Comparison of the antiangiogenic profile of tyrosine kinase inhibitors vorolanib, axitinib,
and sunitinib. Presented at: Retina Society meeting; Oct. 11-14, 2023; New York.
Disclosures:
Bakri reports consulting for EyePoint and Ocular Therapeutix.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.